Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 12/20 | 1.00 |
| ▸ | PDE7B | Q9NP56 | 3/20 | 1.00 |
| ▸ | PDE4A | P27815 | 2/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 2/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18239989 | 0.85 | PDE7A (1.00) | PDE7APDE7BPDE4APDE4BPDE4C | |
| SCHEMBL291137 | 0.83 | PDE7A (1.00) | PDE7APDE7BPDE4APDE4BPDE4C | |
| SCHEMBL30837930 | 0.83 | PDE7A (1.00) | PDE7APDE7BPDE4APDE4BPDE4C | |
| SCHEMBL290341 | 0.83 | PDE7A (0.71) | PDE7APDE7BPDE4APDE4BPDE4C | |
| SCHEMBL29832352 | 0.81 | PDE7A (1.00) | PDE7APDE7BPDE4APDE4BPDE4C | |
| SCHEMBL289913 | 0.81 | PDE7A (1.00) | PDE7APDE7BPDE4APDE4BPDE4C | |
| SCHEMBL19487245 | 0.81 | LMNA (0.77) | PDE7APDE7BPDE4APDE4BPDE4C | |
| SCHEMBL19015256 | 0.78 | PDE7A (0.67) | PDE7APDE7BPDE4APDE4BPDE4C | |
| SCHEMBL9972171 | 0.76 | LMNA (0.74) | PDE7APDE7BPDE4APDE4BPDE4C | |
| SCHEMBL5030398 | 0.76 | MAPT (0.67) | PDE7APDE7BPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4197318-B1 | PHOSPHODIESTERASES INHIBITORS TO PROMOTE IN VITRO PLANT CELL REPROGRAMMING TOWARDS PLANT EMBRYOGENESIS OR MICROCALLUS FORMATION | UNIV FREIBURG ALBERT LUDWIGS (DE) | 2025-11-19 | — | — | EP | claimed |
| US-20250057097-A1 | PHOSPHODIESTERASES INHIBITORS TO PROMOTE IN VITRO PLANT CELL REPROGRAMMING TOWARDS PLANT EMBRYOGENESIS OR MICROCALLUS FORMATION | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2025-02-20 | — | — | US | claimed |
| WO-2023110673-A1 | PHOSPHODIESTERASES INHIBITORS TO PROMOTE IN VITRO PLANT CELL REPROGRAMMING TOWARDS PLANT EMBRYOGENESIS OR MICROCALLUS FORMATION | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2023-06-22 | — | — | WO | claimed |
| EP-4197318-A1 | PHOSPHODIESTERASES INHIBITORS TO PROMOTE IN VITRO PLANT CELL REPROGRAMMING TOWARDS PLANT EMBRYOGENESIS OR MICROCALLUS FORMATION | Albert-Ludwigs-Universität Freiburg (DE) | 2023-06-21 | — | — | EP | claimed |
| EP-4197318-B1 | PHOSPHODIESTERASES INHIBITORS TO PROMOTE IN VITRO PLANT CELL REPROGRAMMING TOWARDS PLANT EMBRYOGENESIS OR MICROCALLUS FORMATION | UNIV FREIBURG ALBERT LUDWIGS (DE) | 2025-11-19 | — | — | EP | disclosed |
| US-20250057097-A1 | PHOSPHODIESTERASES INHIBITORS TO PROMOTE IN VITRO PLANT CELL REPROGRAMMING TOWARDS PLANT EMBRYOGENESIS OR MICROCALLUS FORMATION | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2025-02-20 | — | — | US | disclosed |
| WO-2023110673-A1 | PHOSPHODIESTERASES INHIBITORS TO PROMOTE IN VITRO PLANT CELL REPROGRAMMING TOWARDS PLANT EMBRYOGENESIS OR MICROCALLUS FORMATION | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023110673-A1 | PHOSPHODIESTERASES INHIBITORS TO PROMOTE IN VITRO PLANT CELL REPROGRAMMING TOWARDS PLANT EMBRYOGENESIS OR MICROCALLUS FORMATION | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2023-06-22 | — | — | WO | disclosed |
| EP-4197318-A1 | PHOSPHODIESTERASES INHIBITORS TO PROMOTE IN VITRO PLANT CELL REPROGRAMMING TOWARDS PLANT EMBRYOGENESIS OR MICROCALLUS FORMATION | Albert-Ludwigs-Universität Freiburg (DE) | 2023-06-21 | — | — | EP | disclosed |
| EP-4197318-A1 | PHOSPHODIESTERASES INHIBITORS TO PROMOTE IN VITRO PLANT CELL REPROGRAMMING TOWARDS PLANT EMBRYOGENESIS OR MICROCALLUS FORMATION | Albert-Ludwigs-Universität Freiburg (DE) | 2023-06-21 | — | — | EP | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-11207275-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | OMEROS CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| US-8637528-B2 | Use of PDE7 inhibitors for the treatment of movement disorders | OMEROS CORPORATION (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637528-B2 | Use of PDE7 inhibitors for the treatment of movement disorders | OMEROS CORPORATION (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130267502-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2013-10-10 | — | — | US | disclosed |
| US-20130267502-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2013-10-10 | — | — | US | disclosed |
| US-20120115849-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2012-05-10 | — | — | US | disclosed |
| US-20120115849-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2012-05-10 | — | — | US | disclosed |
| US-20100113486-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113486-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115849-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | PDE7A 10/4885PDE7B 1/4885PDE4A 3/4885 |
| US-11207275-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | PDE7B, PDE4C, PDE4A | PDE7A 10/4885PDE7B 1/4885PDE4A 3/4885 |
| US-20130267502-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | PDE7A 10/4885PDE7B 1/4885PDE4A 3/4885 |
| US-20100113486-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | PDE7A 3/4885PDE7B 2/4885PDE4A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.